On July 21, 2021 Beijing Mabworks Biotech reported that it has filed an application to IPO on the Hong Kong Exchange (Press release, Mabworks Biotech, JUL 21, 2021, View Source [SID1234585071]). The company is developing mAbs and multi-specific antibodies for oncology and autoimmune diseases. Its pipeline consists of six clinical-stage drug candidates and six preclinical candidates, plus an Avastin biosimilar that Mabworks out-licensed to Betta Pharma of Hangzhou. The company’s lead candidate is MIL62, a third-gen CD20 multi-specific that is slated to begin Phase III trials in lymphoma. Because the application was the first filing, no financial details of the IPO were included.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!